Navigation Links
BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
Date:9/8/2009

HERNDON, Va., Sept. 8 /PRNewswire/ -- BHR Pharma, LLC (BHR) announced today that it will initiate a global, Phase 3, multi-center pivotal trial (www.synapse-trial.com) to evaluate the effectiveness of its proprietary BHR-100 intravenous progesterone infusion product as a neuroprotective agent for treating severe traumatic brain injury (TBI) patients in early 2010.

BHR will enroll approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), closed-head trauma TBI at 100-120 medical centers in the United States, Europe, Israel and additional countries.

Randomized patients will receive a five-day (120-hour) intravenous infusion of progesterone or placebo. Unlike intravenous progesterone infusions described in the medical literature, BHR-100 is a ready-to-use infusion designed to meet all U.S. Food and Drug Administration approval requirements.

BHR is collaborating with the American Brain Injury Consortium (ABIC) and the European Brain Injury Consortium (EBIC) to identify the trial sites and help design the clinical study. PRA International is the Contract Research Organization for the trial.

TBI is a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to permanent or temporary impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

Approximately 1.5 million Americans per year suffer a traumatic brain injury, resulting in 50,000 deaths, 235,000 hospitalizations and 80,000 cases of long-term disability. Incidence of TBI in all industrialized countries is comparable to that in the U.S., with estimates ranging from 150 to more than 300 per 100,000. There are approximately 66,000 deaths annually attributed to TBI in Europe.

The leading cause of TBI in the world is road traffic accidents, accounting for 40-50 percent of the hospitalizations for TBI.

There are currently no approved medications to improve outcomes following TBI.

The SyNAPSe study will build on promising results achieved in several previous clinical trials that demonstrated a mortality benefit and improved functional outcomes in TBI patients treated with progesterone. BHR has exclusively licensed the rights to a patent family claiming the use of progesterone to treat traumatic brain injury, along with preclinical and clinical data from a Phase 2 TBI study.

About BHR

Founded in January 2008, BHR Pharma, LLC (www.bhr-pharma.com) is a pharmaceutical research and development (R&D) company located near Washington, DC. BHR is committed to bringing to market specialty treatments that employ non-oral delivery systems, with an emphasis on unmet and underserved medical needs.

A wholly owned subsidiary of Besins Healthcare SA (www.besins-healthcare.com), which markets healthcare products in 93 countries, BHR manages all of Besins' global R&D activities. Those activities primarily leverage proprietary parenteral drug formulations, including the Enhanced Hydroalcoholic Gel (EHG((R))) technology pioneered and commercially launched by Besins in 1975.


'/>"/>
SOURCE BHR Pharma, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
4. Nitec Pharma Reports Positive and Highly Significant Phase III Results From Capra-2 Study of Lodotra(TM) in RA
5. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
6. Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009
7. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
8. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
9. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
10. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
11. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016   AlloSource ... cartilage, cellular, bone, skin and soft-tissue allografts for ... , Business Process Manager, for being named to ... Baldrige National Quality Award by the Commerce Department,s ... the organization,s commitment to process excellence. The Baldrige ...
(Date:12/6/2016)... BOSTON , Dec. 6, 2016  BTL ... evaluation proving that its BTL Vanquish ME device ... homogenous energy delivery to the targeted tissue. The ... reduction, 53% higher, with BTL Vanquish ME versus ... providing our physician network and their patients with ...
(Date:12/6/2016)... opioids commonly used for pain management for workplace injuries, employers now ... to nationwide fatalities. The synthetic opioid called U-47700, or ... morphine, resulting in likelihood of addiction, abuse or death. ... , , ... for HMC HealthWorks, explained the opioid drug is less expensive yet ...
Breaking Medicine Technology:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... offering insurance and financial planning services to families and business owners in the ... funds on behalf of the Dallas Fallen Officer Foundation. , Established in 2009 ...
(Date:12/7/2016)... , ... December 07, 2016 , ... A. Kevin Spann ... and families throughout the Five Boroughs, is launching a charity drive to raise funds ... continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... announce that its fully redesigned website, which launched October 17, 2016, features comprehensive ... responsive design and easy-to-navigate layout. Visitors and patients can discover the latest clinical ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is condemning "scam operations" carried out by unethical locksmith companies and is urging ... to a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to ... Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip ... zones. Editors can select from a variety of flip book animations. In Addition, users ...
Breaking Medicine News(10 mins):